Drug Profile
Research programme: platelet ADP receptor antagonists - Pfizer
Alternative Names: BX 667Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Berlex
- Developer Pfizer
- Class Piperazines
- Mechanism of Action Platelet ADP receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA (PO)
- 26 Mar 2010 Preclinical development is ongoing in USA